GSK Promotes Ease Of Switching HIV Patients To Monthly Injection, Even During A Pandemic

Aiming To Seize Market Share From Gilead

 
• By Andrew McConaghie

Doctors and patients need to be persuaded of the benefits of switching from familiar oral therapies to Cabenuva, the once-monthly anti-HIV injection. 

GSK
GSK is depending on Cabenuva to be one of its next generation of blockbusters. • Source: Alamy

More from Business

More from Scrip